Jakubowitz Law
20.7.2021 15:46:47 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Virgin Galactic Holdings, Inc. (NYSE:SPCE)
CONTACT JAKUBOWITZ ABOUT SPCE:
https://claimyourloss.com/securities/virgin-galactic-holdings-inc-loss-submission-form/?id=17803&from=1
Class Period : October 26, 2019 - April 30, 2021
Lead Plaintiff Deadline: July 27, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
CONTACT JAKUBOWITZ ABOUT FREQ:
https://claimyourloss.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=17803&from=1
Class Period : November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
Ocugen, Inc. (NASDAQ:OCGN)
CONTACT JAKUBOWITZ ABOUT OCGN:
https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=17803&from=1
Class Period: February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline: August 17, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/656265/Lawsuits-Filed-Against-SPCE-FREQ-and-OCGN--Jakubowitz-Law-Pursues-Shareholders-Claims
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM)31.3.2026 15:15:00 CEST | Press release
$100 Million in Initial Coppercoin™ Issuance to Set Industry Standard in Tokenized Copper PHILADELPHIA, PA / ACCESS Newswire / March 31, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and Coppercore Inc. ("Coppercore") today announced the closing of a definitive agreement to digitize and tokenize significant copper resources. The transaction enables Datavault AI to deploy its patented IDE®, DataScore®, and DataValue® blockchain tokenization platform to create Coppercoin™ digital tokens representing pro-rata ownership interests in the underlying in-ground resources. The initial program targets the minting of $100 million or more in Digital Copper Tokens. Coppercoin™ tokens are structured such that each token corresponds to five pounds of underlying high-grade copper resources, with pricing directly linked to the COMEX copper benchmark on a pe
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
The World's First Agentic CMS Just Got Smarter: Kontent.ai Launches Expert Agents31.3.2026 09:00:00 CEST | Press release
Kontent.ai, the team behind the world's first Agentic CMS, today announced the launch of Expert Agents: purpose-built AI agents that bring deep, specialized intelligence to the content operations teams manage every day. Expert Agents work continuously across content workflows, handling everything that doesn't require human judgment. They can be configured by anyone using simple natural language prompts. BRNO, CZ / ACCESS Newswire / March 31, 2026 / Expert Agents help organizations move faster than ever before, augmenting teams without adding headcount, accelerating campaign launches across markets, improving content performance at scale, and reducing regulatory and compliance risk across even the largest content inventories. The launch marks the next step in Kontent.ai's Agentic CMS vision: a platform where AI agents are embedded directly into the operational layer of content management. At its core, the Agentic CMS combines two layers of intelligence: the Main Agent, which lets teams
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy30.3.2026 16:55:00 CEST | Press release
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate
CORRECTION: Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 16:25:00 CEST | Press release
This Press Release updates the previous version that had incorrect information Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom